Clinical value of natriuretic peptides in chronic kidney disease  by Santos-Araújo, Carla et al.
nefrologia. 2 0 1 5;35(3):227–233
Revista de la Sociedad Española de Nefrología
w w w.rev is tanef ro logia .com
Review
Clinical  value  of  natriuretic  peptides  in  chronic
kidney disease
Carla Santos-Araújoa,∗, Adelino Leite-Moreirab, Manuel Pestanac
a Department of Physiology and Cardiothoracic Surgery, Cardiovascular R&D Center and Nephrology and Infectious Diseases Research
and Development Group, INEB (I3S) Faculty of Medicine, University of Porto, Porto, Portugal
b Department of Physiology and Cardiothoracic Surgery, Cardiovascular R&D Center, Faculty of Medicine, University of Porto, Porto,
Portugal
c Nephrology and Infectious Diseases Research and Development Group, INEB (I3S) and Department of Renal, Urologic and Infectious
Diseases, Faculty of Medicine, University of Porto, Porto, Portugal
a  r  t  i  c  l  e i  n  f o
Article history:
Received 1 September 2014
Accepted 9 March 2015
Available online xxx
Keywords:
B-type natriuretic peptide
N-terminal-pro-BNP
Heart failure
Chronic kidney disease (CKD)
Dialysis
a  b  s  t r  a c  t
According to several lines of evidence, natriuretic peptides (NP) are the main components
of a cardiac-renal axis that operate in clinical conditions of decreased cardiac hemody-
namic tolerance to regulate sodium homeostasis, blood pressure and vascular function.
Even though it is reasonable to assume that NP may exert a relevant role in the adaptive
response to renal mass ablation, evidence gathered so far suggest that this contribution is
probably complex and dependent on the type and degree of the functional mass loss.
In the last years NP have been increasingly used to diagnose, monitor treatment and deﬁne
the prognosis of several cardiovascular (CV) diseases. However, in many clinical settings, like
chronic kidney disease (CKD), the predictive value of these biomarkers has been questioned.
In fact, it is now well established that renal function signiﬁcantly affects the plasmatic levels
of NP and that renal failure is the clinical condition associated with the highest plasmatic
levels of these peptides. The complexity of the relation between NP plasmatic levels and CV
and renal functions has obvious consequences, as it may limit the predictive value of NP in
CV  assessment of CKD patients and be a demanding exercise for clinicians involved in the
daily management of these patients.
This review describes the role of NP in the regulatory response to renal function loss and
addresses the main factors involved in the clinical valorization of the peptides in the context
of signiﬁcant renal failure.
© 2015 The Authors. Published by Elsevier España, S.L.U. on behalf of Sociedad Española
de Nefrología. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Utilidad  clínica  de  los  péptidos  natriuréticos  en  la  enfermedad  renal
crónica
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Diálisis
r  e  s  u  m  e  n
Existen varias líneas de evidencia que indican que los péptidos natriuréticos (PN) son los
componentes principales de un eje cardio-renal que actúa en situaciones clínicas de reduc-
ción de la tolerancia hemodinámica cardiaca mediante la regulación de la homeostasis del
sodio, la presión arterial y la función vascular. A pesar de que parece razonable asumir que
los PN puedan desempen˜ar un papel importante en la respuesta adaptativa a la ablación de
masa renal, la evidencia acumulada hasta ahora sugiere que esta contribución es probable-
mente compleja y depende del tipo y el grado de pérdida de masa funcional.
En los últimos an˜os los PN se han venido utilizando de manera creciente para diagnos-
ticar, realizar un seguimiento del tratamiento y deﬁnir el pronóstico de varias enfermedades
cardiovasculares (CV). Sin embargo, en varios contextos clínicos, como el de la enfermedad
renal crónica (ERC), se ha puesto en duda el valor predictivo de esos biomarcadores. De
hecho, actualmente está bien establecido que la función renal inﬂuye signiﬁcativamente en
los niveles plasmáticos de PN y que la insuﬁciencia renal es el estado clínico que se asocia
a  unos niveles plasmáticos más elevados de estos péptidos. La complejidad de la relación
existente entre los niveles plasmáticos de PN y la función CV y renal tiene consecuencias
obvias, puesto que puede limitar el valor predictivo de los PN en la evaluación CV de los
pacientes con ERC y su uso puede requerir un esfuerzo adicional por parte de los clínicos
encargados del manejo cotidiano de esos pacientes.
En esta revisión se describe el papel que desempen˜an los PN en la respuesta reguladora
ante la pérdida de función renal, y se abordan los principales factores involucrados en
el valor clínico que se asigna a los péptidos en el contexto de una insuﬁciencia renal
signiﬁcativa.
©  2015 The Authors. Publicado por Elsevier España, S.L.U. en nombre de Sociedad Española
de Nefrología. Este es un artículo Open Access bajo la licencia CC BY-NC-ND
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Natriuretic peptides (NP) are a family of hormones, sharing
similar chemical structure and biological function, with rele-
vant effects in cardiovascular (CV) physiology and pathology.
The classical physiological role of NP includes promotion of
renal excretion of sodium and water, contributing to blood
pressure (BP) regulation. Additionally, NP also exert autocrine
and paracrine actions within the circulation, namely vasodi-
lation through the relaxation of vascular muscle cells,
anti-ﬁbrotic and anti-proliferative effects and regulation of
renin, progesterone, endothelin and vasopressin secretion.1
In conditions of acute or chronic volume overload, NP may
have an important role as counter-regulatory hormones that
compensate the effects of vasoconstrictor-mitogenic-sodium
retaining hormones, released by the sympathetic nervous
system and the renin–angiotensin–aldosterone system, con-
tributing to the maintenance of circulatory  homeostasis.2
Additionally, NP have been previously implicated as possi-
ble mediators of the integrated response to functional renal
mass loss, with a distinct contributory role depending both on
the degree of renal failure and on the time elapsed from the
beginning of renal function decline.
The disease state associated with the highest circulating
levels of NP is renal failure.3 In this setting, increased NP cir-
culating levels cannot linearly be interpreted as an expression
of the activation of the NP system, as observed in the context
of left ventricle (LV) wall stress associated with heart failure
(HF) or volume overload. Indeed, previous evidence from a
number of studies have suggested that plasmatic levels of
NP may be regulated both by the rate of synthesis/cardiac
release of NP and by the rate of removal of the peptides from
the circulation.4,5 As a consequence, NP circulating levels in
patients with signiﬁcant renal failure have to be interpreted in
light of the severity of renal dysfunction and a higher cut point
is expected as chronic kidney disease (CKD) stage advances.
The aim of the present work is to review the role of the
NP system in the adaptive response to renal function loss
and to address the clinical utility of NP circulating levels in
the CV management of patients with severely impaired renal
function.
Natriuretic  peptide  system
Natriuretic peptides play a major role in the maintenance of
sodium and body volume homeostasis and in the modulation
of the proliferative and ﬁbrotic responses.6,7 Four members of
the NP family have been described so far, all sharing a common
17-amino acid ring structure. Atrial NP (ANP) is produced in the
cardiac atria and is secreted in response to an increased atrial
wall tension.8 B-type natriuretic peptide (BNP) is synthesized
as an amino acid precursor protein (pro-BNP) and released
from the ventricles in response to increased ventricular wall
stress.9 On secretion, the pro-BNP hormone is cleaved in a 1:1
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equimolar ratio to a 32-amino acid C-terminal fragment (BNP)
that is biologically active and a 76-amino acid N-terminal
fragment (N-terminal pro-BNP – NT-pro-BNP), which is bio-
logically inactive. Compared with BNP, NT-pro-BNP has the
advantage of having a longer plasma half-life and lower bio-
logic variation.10 There are two types of C-type NP (CNP): a
22-amino acid form, more  potent and secreted in the central
nervous system and endothelial tissue in response to shear
stress; and a 52-amino acid form.11 All these types of NP can
be detected in human plasma. D-type NP (DNP) is found in the
venom of green mamba  snake and the primary stimulus and
main function are still currently unknown in humans.12
B-type  natriuretic  peptide
B-type natriuretic peptide was  originally isolated in extracts
from porcine brain in 1988 but was rapidly recognized to
be largely synthesized and released from the ventricles in
response to LV wall stress.13 BNP exerts most of its cellular
effects through the activation of the transmembrane guany-
lyl cyclase, natriuretic peptide receptor-A (NPR-A).14 Another
natriuretic peptide receptor, natriuretic peptide receptor-C
(NPR-C), is devoid of guanyl cyclase activity and is responsible
for NP internalization and degradation.15 However, NPR-C may
not behave exclusively as a clearance receptor but could also
illicit physiological functions through the inhibition of adeny-
lyl cyclase signal transduction system, interfering with the cel-
lular mechanisms involved in the regulation of cell growth.15
Increased circulating levels of BNP can be observed in
several disease states and are generally interpreted as an
expression of the activation of the NP system. However,
plasma concentration of BNP is regulated simultaneously both
by the rate of synthesis and release of NP and by the rate
of removal of the peptides from the circulation.16 The clear-
ance of BNP involves two pathways: enzymatic degradation
by neutral endopeptidase and receptor-mediated endocytosis
followed by lysosomal degradation via the NPR-C.6 Despite the
fact that the relative importance of these two mechanisms in
the removal of NP from the circulation is still controversial,
it has been previously demonstrated in NPR-C knockout mice
that the absence of this clearance mechanism is associated
with signiﬁcant prolonged plasmatic half-life of exogenous
BNP.17 Additionally, the modulation of target organ receptor
expression may be determinant for the local bioavailability
of NP and, by that mechanism, play an important role in the
regional control of the NP system activity. Therefore, the local
actions of NP can be limited both by increased NPR-C renal
expression and/or by NPRA downregulation. In accordance to
this, several lines of evidence have suggested that resistance
to NP related to changes in the renal expression of NPR-A may
explain in part the maintenance of volume expansion (VE) in
edema formation conditions, namely in congestive HF.18,19
In normal subjects NT-pro-BNP is continuously released
from the heart and can be measured in plasma, in equiva-
lent concentrations with BNP. However, in patients with LV
dysfunction, by mechanisms not yet clariﬁed, NT-pro-BNP
concentration is systematically higher than that of BNP. Based
on this, some authors advocate that NT-proBNP plasmatic lev-
els may be a better marker of HF progression.20
BNP  and  adaptation  to  functional  renal  mass
loss
Uninephrectomy
The removal of a single kidney immediately stimulates the
growth and function of the remnant renal mass. This acute
compensatory response is recognized during the ﬁrst days
after unilateral nephrectomy (Unx) and is characterized by
an increase in electrolyte excretion, a mild decrease in car-
diac output and a transient rise in BP.21 Some weeks later, a
time-dependent increase in both systolic and diastolic BP is
observed, together with a sustained reduction in the natri-
uretic response to VE, suggesting that the relative role of the
natriuretic systems in the control of sodium balance may dif-
fer overtime.22
Atrial natriuretic peptide has been previously implicated
as a possible mediator of the acute renal response to
contralateral renal ablation. Indeed, previous studies have
documented a suppressed natriuretic response to Unx in a
rat model of diminished ANP release obtained by right atrial
appendectomy.23 The importance of the NP system in the
regulation of sodium balance in response to unilateral renal
ablation was also reinforced by the observation of an impaired
renal sodium excretion response after the blockade of circu-
lating ANP by monoclonal antibodies in an animal model of
Unx.24 The role of BNP, the selective renal modulation of both
the effector (NPR-A) and the clearance (NPR-C) NPR and, more
importantly, the time course of these changes after Unx were
recently described in a rat model of uninephrectomy.25 In this
study, the renal up-regulation of NPR-A combined with the
down-regulation of NPR-C suggested that the renal NP system
may be an important mediator of the long-term regulation of
salt and water balance, extracellular ﬂuid volume and BP after
Unx, partially counteracting the blunted activity documented
in other neuro-humoral natriuretic systems.26 Additionally, it
was suggested that the local changes in NPR-C expression
in the renal medulla of Unx rats, resulting in a decreased
expression of this receptor, could operate as a contributing
factor for the compensatory growth observed after unilateral
renal ablation, supporting an important role of the NP in the
compensatory response observed after Unx. Nevertheless, the
exact function of the NP system in the regulation of the adap-
tive response to unilateral renal mass ablation remains to be
fully clariﬁed.
Chronic  kidney  disease
In CKD, an increase in NP circulating levels was observed and
implicated in the compensatory increase in glomerular ﬁltra-
tion rate (GFR) and in the decrease in sodium reabsorption,
both under normal and salt-replete conditions.27 Although
CKD is frequently associated with disturbances in CV hemo-
dynamics, the mechanisms responsible for the increase of NP
circulating levels in this condition still remain to be elucidated.
Indeed, an elevation of BNP circulating levels was previously
described in normal aged subjects in the absence of cardiac
dysfunction and this was attributed to a decrease in the renal
clearance of NP.28,29 Additionally, renal failure per se has also
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been shown to affect the plasmatic levels of BNP, a condition
not signiﬁcantly altered by renal replacement therapy, namely
peritoneal dialysis (PD).30,31
It is not completely clariﬁed if the elevation in NP plas-
matic levels in CKD reﬂects an activation of the system
and effectively results in target organ stimulation. This is
a matter of considerable importance given that substantial
increments of plasma NP in patients with CKD lead to a
modest natriuretic response when compared to normal con-
trols or to glomerulonephritic patients with well-preserved
renal function.32 Additionally, the effects of NP on glomerular
hemodynamics were suggested to occur independently from
those related to the decrease of sodium reabsorption in renal
tubules,33 implying a prominent role for target organ receptor
expression in the control of system activity.
Evidence that the modulation of target organ receptor
expression may be determinant for the local bioavailability of
NP in CKD and, by that mechanism, play an important role in
the regional control of the NP system activity was reinforced
in a rat experimental model of renal insufﬁciency induced by
¾ nephrectomy (¾nx). In this study, BP elevation and compro-
mised natriuretic response to VE in ¾nx rats was associated
with a precocious and time-dependent increase in circulat-
ing BNP levels, in the absence of cardiac dysfunction. These
changes were accompanied by an early, selective and sus-
tained impaired expression of NPR-A in the renal medulla
along with an upregulation of NPR-C in the renal cortex, sug-
gesting a distinct modulation of NPRs in the remnant kidney
that could deﬁne a possible mechanism for NP resistance in
CKD.34 This could help to explain some of the disappointing
results observed both with NP infusion in the renal protec-
tion against toxin-induced renal failure and in renal function
preservation of patients with decompensated HF35,36 and limit
the clinical use of NP in the treatment of cardio-renal dysfunc-
tion.
Clinical  utility  of  BNP  and  NT-pro-BNP  in
chronic  kidney disease
Several studies in patients with HF showed that BNP secretion
from ventricular myocytes increases in relation to the degree
of dysfunction and substantiated the use of these peptides in
the diagnosis, screening, prognosis and monitoring of therapy
of patients with CV conditions.37,38 Indeed, therapies aiming
to reduce the clinical manifestations of HF seem to act pri-
marily through mechanisms that are linked to changes in NP
levels, allowing the clinician to guide therapy and adjust the
treatment in order to achieve a plasmatic level of these agents
below a critical value. In renal failure, however, the role of NP
as hemodynamic biomarkers is not straightforward.
NP  plasmatic  levels  and  renal  function
Renal function affects the plasmatic levels of both BNP and
NT-pro-BNP. The factors responsible for elevated levels of NP in
CKD are not fully clariﬁed, but the reduced renal clearance of
these peptides may not be the main operating mechanism.39
Alternative explanations include the possibility of decreased
renal responsiveness attributed to the reduction in functional
renal mass, reduced second messenger production and
decreased removal of NP by the clearance receptor in the
renal tissue.40 Some evidence supporting some of these mech-
anisms has already been addressed in this paper. Despite
this, the weight of evidence gathered so far suggests that the
elevations in NP observed in severe renal dysfunction may be
mainly related to a counter-regulatory response directed from
the heart to the kidney, supporting the use of these agents as
potential markers of LV remodeling in CKD patients.41
NP  circulating  levels  and  cardiac  dysfunction  in  renal
failure
Recent evidence suggests that circulating BNP levels strongly
reﬂects the LV end-diastolic wall stress both in patients with
systolic and diastolic heart failure, a correlation maintained
even in the presence of signiﬁcant renal failure.42 Indeed,
studies performed with both hemodialysis (HD) and PD
patients demonstrated that BNP circulating levels maintained
a signiﬁcant potential value in detecting LV hypertrophy and in
ruling out systolic dysfunction in this population.43,44 Despite
this, renal function is systematically identiﬁed as a major
confounding factor in the interpretation of elevated BNP and
NT-pro-BNP and a potential limitation in the current utility
of NP in the CKD population.45 In fact, an increase of BNP
plasmatic levels reaching about 200 pg/ml has been previously
reported in patients with reduced creatinine clearance in the
absence of cardiac dysfunction30 whereas NT-pro-BNP refer-
ence values of 1200 pg/ml have been recommended in this
population.39 Consequently, as CKD stage advances a higher
cutpoint of these NP is implied. NT-pro-BNP plasmatic levels
seem to have a stronger relation with GFR and be more  inﬂu-
enced by the normal age-related decline in renal function than
circulating BNP levels.40 For that reason, some authors advo-
cate that below a GFR of 60 ml/min/1,73 m2 and in the elderly,
NT-pro-BNP plasmatic levels should be used carefully.
NP  plasmatic  levels  in  end  stage  renal  disease  on  dialysis
The effect of HD on both BNP and NT-pro-BNP plasmatic levels
is not entirely clariﬁed and some conﬂicting results have been
reported. Several studies document a predictable elevation
of BNP and NT-pro-BNP in end-stage renal disease patients
before dialysis and a signiﬁcant drop in BNP plasmatic lev-
els of about 20–40% after a HD session.46 This reduction in
BNP and NT-pro-BNP levels after the dialysis treatment may
be explained by the increased dialytic clearance or by the
improved volume control resulting in decreased LV wall stress
and reduced secretion of these peptides from the ventricular
myocardium.47 Elevated levels of BNP and NT-pro-BNP have
been repeatedly documented in PD patients but, unlike what
is observed in HD, PD does not seem to alter signiﬁcantly the
plasmatic levels of these peptides.48
NP  plasmatic  levels  and  volume  status  on  dialysis
Given that both BNP and NT-pro-BNP circulating levels rise
in response to increased ventricular wall stress and decrease
after a HD session, it is tempting to hypothesize that BNP
and NT-pro-BNP circulating levels may be useful markers
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of volume status. Numerous studies have evaluated the
potential role of BNP and NT-pro-BNP in volemia assess-
ment and dry weight determination of HD patients, but the
results remain inconclusive. In fact, whereas some authors
have demonstrated a relation between body ﬂuid distri-
bution assessed by bioimpedance and circulating BNP and
NT-pro-BNP levels,49,50 others failed to establish signiﬁcant
correlations at this level.51 Ultimately, the lack of a consistent
association between BNP and NT-pro-BNP and changes in
ﬂuid volume during HD indicates that BNP and NT-pro-BNP
are not pure markers of volume status in these patients.
Instead, circulating levels of NP in CKD patients most likely
reﬂect increased wall stress resulting simultaneously from LV
hypertrophy, systolic dysfunction and volume overload.
The usefulness of NP in the diagnosis of volume status in
patients on PD is still widely debated. Some studies failed to
show a positive association between clinical volume assess-
ment and BNP or NT-pro-BNP levels in chronic PD patients,
leading to the conclusion that NP are inadequate volume
assessment tools in this subgroup of patients.52,53 In agree-
ment with prior studies performed on HD patients, higher
levels of serum BNP and NT-pro-BNP were also found in PD
patients when compared to normal subjects, in strong cor-
relation with LV hypertrophy and LV ejection fraction.53,54 On
the contrary, other authors demonstrated a signiﬁcant positive
correlation between BNP circulating levels and ﬂuid overload
in stable PD patients, particularly during the ﬁrst months of
treatment, suggesting that BNP measurements may be a use-
ful tool in clinical circumstances where the volume status is
difﬁcult to deﬁne.55
NP  plasmatic  levels  in  different  dialysis  modalities
In PD patients, signiﬁcantly lower plasmatic BNP levels have
been described, when compared to HD patients, supporting
the hypothesis that cardiac load in PD patients may be lower
than that of HD patients.56,50 In fact, it is recurrently attributed
to PD improved stable hemodynamic conditions, lower inci-
dence of systemic hypertension, higher urine output and
slower rate of ultraﬁltration.57 Despite the lower levels of BNP
in PD, it remains inconclusive whether PD is associated with
better volume and BP control when compared to HD and the
true signiﬁcance of this ﬁnding remains to be clariﬁed. Dif-
ferences in BNP circulating levels were also reported when
we consider the two available PD modalities: automated PD
(APD) and continuous ambulatory PD (CAPD). According to
some authors, treatment with APD seems to be associated
with higher plasmatic BNP levels; a ﬁnding presumed to result
from the chronic ﬂuid retention and increased LV hypertro-
phy caused by lower ultraﬁltration frequently observed in APD
patients when compared to CAPD patients.58
Prognostic  value  of  NP  plasmatic  levels  in  dialysis  patients
In both HD and PD patients, cardiac NP are reliable predictors
of death independently of the effect of dialysis modality
on ﬂuid volume control and the presence of other clinical
and biochemical markers recognized as risk factors for all
cause and CV mortality.59 However, not all members of the
NP family have the same predictive value. Indeed, some
studies directly comparing BNP and NT-pro-BNP plasmatic
levels suggest that NT-pro-BNP may be slightly superior to
BNP in predicting death, a ﬁnding attributed to the longer
half-life of NT-pro-BNP and to the better accurate index of
this peptide for LV hypertrophy.60 For all this, some authors
suggest that BNP, and particularly NT-pro-BNP, may be of
value simultaneously in guiding risk stratiﬁcation and in
targeting therapeutic interventions in the CKD population.61
NP  in  renal  transplant
The clinical value of NP has been previously addressed in
renal transplant recipients (RTR) in selected clinical settings.
Indeed, elevated NP levels have been shown to predict hyper-
volemia and allograph dysfunction in stable RTR, what may
be valuable in the objective measurement of extracellular vol-
ume status in these patients.62 Additionally, NP may be useful
for the detection of LV diastolic dysfunction in RTR, particu-
larly if GFR is considered as a confounding factor.63 Plasmatic
levels of NP also have a positive relation with LV hypertrophy
in hypertensive RTR and were proposed in this clinical setting
to screen transplant patients at risk of LV hypertrophy.64 In liv-
ing kidney transplant the information concerning the clinical
value of NP is scarce and studies evaluating the signiﬁcance
and utility of NP levels in living donors are virtually inexistent.
Key  concepts
• BNP and NT-pro-BNP are cardiac biomarkers of cardiovas-
cular morbidity and mortality in patients with normal renal
function and have diagnostic, therapeutic and prognostic
value in patients with heart failure.
• The role of NP in sodium homeostasis after renal mass
ablation seems to be signiﬁcantly inﬂuenced by the local
modulation of the renal NP system and may differ according
to the degree of functional renal mass loss.
• Renal function affects the plasmatic levels of both BNP  and
NT-pro-BNP and may limit their utility as hemodynamic
biomarkers in renal failure.
• NP plasmatic levels have been correlated to left ventricular
structure and function in both hemodialysis and peritoneal
dialysis patients, but this association may be signiﬁcantly
affected by other factors operating in severe renal function
deterioration.
• The usefulness of NP in the diagnosis of volume status
in patients on dialysis is still widely debated and partially
depends on the degree of peptide clearance by the different
dialysis techniques.
• Despite this, in dialysis patients cardiac NP are reliable pre-
dictors of death independently of the dialysis modality and
of the degree of ﬂuid volume control and may be of value in
the early identiﬁcation of a subgroup of patients at a higher
mortality risk.
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